High Response Rate to Bexxar in Advanced Stage Prior Treatment-Resistant Follicular Lymphoma
March 2005
in “
Cancer biology & therapy
”
Studysummary This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on tandfonline.com →